Oncology

Cell and gene therapy
#Adverse event #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #FDA #Immunotherapy #ISCT #Oncology

Experts comment on FDA report on risk of T-cell malignancy  

The International Society for Cell & Gene Therapy (ISCT) has announced the publication in Nature Medicine of an expert consortium commentary addressing a recent statement from the US Food & Drug Administration (FDA) that it is investigating serious risk of T-cell malignancy… Read More

#News #Regulatory

Business agreement
#Colorectal cancer #Inspirna #License agreement #Merck #Oncology #Phase II trial

Merck expands colorectal cancer portfolio with ompenaclid

Merck has agreed a deal with Inspirna for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer… Read More

#Business & Investment #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

#Breast cancer #Collaboration #Mayo Clinic #Oncology #Precision medicine #SimBioSys

US collaboration to advance precision drugs for breast cancer

Techbio SimBioSys and the Mayo Clinic have entered into a strategic collaboration to develop novel digital precision medicine solutions for breast cancer. The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients,… Read More

#Business & Investment #News

Dr Maud Dumoux, the Franklin, and Dr Victor Bolanos-Garcia, Oxford Target Therapeutics.
#Breast cancer #Funding #Oncology #Oxford Target Therapeutics #Rosalind Franklin Institute

Cancer drug discovery company wins £50K research residency

Oxford Target Therapeutics, a company developing a promising therapy for triple negative breast cancer, is one of three UK life science companies awarded research prizes by the Rosalind Franklin Institute, based in Oxfordshire, UK. The prizes, awarded in collaboration with the Science and Technology Facilities Council… Read More

#News

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

New DDW Highlights podcast for 27 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There have been some ground-breaking advances in women’s health this week, with new treatments… Read More

#News

#Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Neuroscience #Oncology

DDW readers’ top drug discovery developments of 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Bladder cancer #Breast cancer #Depression #Menopause #Oncology #Psychedelics #Women's health

This week in drug discovery (18-22 December) 

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More

#News

Woman reading on a tablet
#2023 #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Biotech hubs #Cell and gene therapy #CRISPR #Diversity #Oncology #Regulatory

DDW top reads in 2023

DDW’s Senior Digital Content Editor Diana Spencer reviews the year’s top ten articles. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy… Read More

#Exclusive Content

Breast cancer cell
#Breast cancer #Cancer research #Oncology #The Institute of Cancer Research

Discovery lights the way for new secondary breast cancer drugs

Using a novel approach, researchers from The Institute of Cancer Research, London have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing effective treatments. The study revealed for the first time that breast cancer leptomeningeal metastasis (BCLM) cells… Read More

#Cancer Research #News

Bladder cancer
#Antibody drug conjugate (ADC) #Astellas Pharma #Bladder cancer #FDA #Oncology #Pfizer #Phase III trial

Bladder cancer therapy reduces risk of death by 50%

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). The approval is based on clinical data which found that Padcev plus pembrolizumab nearly doubled median… Read More

#Editor's Choice #News #Regulatory

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

New DDW Highlights podcast for 19 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on haematology, thanks in part to a number… Read More

#News

Patient speaking to psychiatrist
#Depression #Major depressive disorder #Oncology #Phase II trial #Psychedelics #Sunstone Therapies

Psychedelic reduces depressive symptoms in cancer patients

Results from a Phase II clinical trial indicate that psilocybin may benefit individuals with cancer and major depression. In the study, trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy when interviewed at the end… Read More

#News #Trending News

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

This week in drug discovery (11-15 December) 

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of… Read More

#News

Myeloma cells
#Blood cancer #CellCentric #Haematology #Myeloma #Oncology #Phase I trial

New class of drug shows promise in last line multiple myeloma

Data presented at the American Society for Hematology meeting (ASH) show a 70% response rate in last line multiple myeloma patients treated with CellCentric’s inobrodib in combination with pomalidomide (pom) and dexamethasone (dex). Inobrodib is the first in a new class of drug, which disrupts the… Read More

#Cancer Research #News